BDBM331864 US10189853, Compound 8

SMILES COc1ccc2NC(Cc2c1)N(C)c1nc(C)nc2oc(C)cc12

InChI Key InChIKey=WJOBXFAFXPJZEZ-UHFFFAOYSA-N

Data  3 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 331864   

TargetEpidermal growth factor receptor(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM331864(US10189853, Compound 8)
Affinity DataIC50: 103nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM331864(US10189853, Compound 8)
Affinity DataIC50: 20.9nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit

US Patent
LigandPNGBDBM331864(US10189853, Compound 8)
Affinity DataIC50: 73.2nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent